Erika Yorida

2.3k total citations
14 papers, 1.2k citations indexed

About

Erika Yorida is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erika Yorida has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erika Yorida's work include HER2/EGFR in Cancer Research (6 papers), Cancer-related Molecular Pathways (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Erika Yorida is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer-related Molecular Pathways (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Erika Yorida collaborates with scholars based in Canada, United States and Germany. Erika Yorida's co-authors include Maggie C.U. Cheang, David G. Huntsman, Dmitry Turbin, C. Blake Gilks, Sandra E. Dunn, H. Leighton Grimes, Torsten O. Nielsen, Cathy Lee, C. Blake Gilks and Nikita Makretsov and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Erika Yorida

14 papers receiving 1.2k citations

Peers

Countries citing papers authored by Erika Yorida

Since Specialization

Citations

This map shows the geographic impact of Erika Yorida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Yorida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Yorida more than expected).

Fields of papers citing papers by Erika Yorida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Yorida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Yorida. The network helps show where Erika Yorida may publish in the future.

Co-authorship network of co-authors of Erika Yorida

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Yorida. A scholar is included among the top collaborators of Erika Yorida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Yorida. Erika Yorida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Title	Journal	Authors	Indexed citations
1	A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations	Journal of Molecular Diagnostics	Ian Bosdet, Roderick Docking et al.	24
2	Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients	Pathology	Michelle Wong, Maggie C.U. Cheang et al.	35
3	Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer	Cancer Letters	David G. Huntsman, Erika Yorida et al.	27
4	Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2	Cancer Research	Joyce C. Wu, Cathy Lee et al.	136
5	Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease	Clinical Breast Cancer	Andrew Robinson, Dmitry Turbin et al.	22
6	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells	Oncogene	Brent W. Sutherland, Jill E. Kucab et al.	249
7	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis	Oncogene	Leah Prentice, Ashleen Shadeo et al.	52
8	MDM2 protein expression is a negative prognostic marker in breast carcinoma	Modern Pathology	Dmitry Turbin, Maggie C.U. Cheang et al.	65
9	Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival	Cancer	Sam M. Wiseman, Nikita Makretsov et al.	88
10	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours	Breast Cancer Research	Jill E. Kucab, Cathy Lee et al.	76
11	Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer	Journal of Clinical Oncology	Andrew Robinson, Susan Ellard et al.	10
12	p63 Expression in Lung Carcinoma	Applied immunohistochemistry & molecular morphology	Nicholas Au, A M Gown et al.	134
13	Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers	The Journal of Pathology	Nicholas Au, Maggie C.U. Cheang et al.	106
14	Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma	Clinical Cancer Research	Nikita Makretsov, David G. Huntsman et al.	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact